Active, not recruitingPhase 2NCT05419011
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Studying Hereditary nonpolyposis colon cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ajay BansalUniversity of Kansas
- Intervention
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5(biological)
- Enrollment
- 186 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (14)
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- University of Colorado, Denver, Colorado, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- University of Puerto Rico, San Juan, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05419011 on ClinicalTrials.govOther trials for Hereditary nonpolyposis colon cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07163403First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome CarriersFundacion Clinic per a la Recerca Biomédica
- RECRUITINGPHASE1, PHASE2NCT06898450A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.Nimbus Wadjet, Inc.
- RECRUITINGNANCT05963191CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch SyndromePERROD Guillaume
- RECRUITINGNCT06708429Lynch Syndrome X-Talk of Enteral Mucosa With Immune SystemSan Raffaele University
- RECRUITINGNANCT07219537A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE CapsuleMassachusetts General Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT05078866Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT02813824Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGNCT02371135Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis SyndromesMemorial Sloan Kettering Cancer Center